Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI.

Saumya S. Gurbani, Emory University
Younghyoun Yoon, Emory University
Brent Weinberg, Emory University
Eric Salgado, Emory University
Robert H. Press, Emory University
J. Scott Cordova, Emory University
Karthik K. Ramesh, Emory University
Zhongxing Liang, Emory University
Jose Velazquez Vega, Emory University
Alfredo Voloschin, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: Tomography : a journal for imaging research
Volume: Volume 5, Number 1
Publisher: Grapho Publications, LLC | 2019-03, Pages 53-60
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.18383/j.tom.2018.00031
Permanent URL: https://pid.emory.edu/ark:/25593/tnz4k

Final published version: http://dx.doi.org/10.18383/j.tom.2018.00031

Copyright information:
© 2019 The Authors
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed August 3, 2019 1:49 PM EDT
Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI

Saumya S. Gurbani1,2, Younghyoun Yoon1, Brent D. Weinberg3, Eric Salgado1, Robert H. Press1, J. Scott Cordova1, Karthik K. Ramesh1,2, Zhongxing Liang1, Jose Velazquez Vega4, Alfredo Voloschin5, Jeffrey J. Olson6, Eduard Schreibmann1, Hyunsuk Shim1,2,3, and Hui-Kuo G. Shu1

1Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; 2Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA; Departments of 3Radiology and Imaging Sciences, 4Pathology and Laboratory Medicine; 5Hematology and Medical Oncology, and 6Neurosurgery, Emory University School of Medicine, Atlanta, GA

Corresponding Authors: Hyunsuk Shim, PhD
Department of Radiation Oncology, Winship Cancer Institute of Emory University, 1701 Uppergate Drive, Atlanta, GA 30322;
E-mail: hshim@emory.edu; and Hui-Kuo Shu,
E-mail: hshu@emory.edu

Key Words: glioblastoma, spectroscopic MRI, histone deacetylase inhibitor, belinostat, orthotopic rat glioma model

Abbreviations: Histone deacetylase inhibitors (HDACi), glioblastoma (GBM), progression-free survival (PFS), radiation therapy (RT), temozolomide (TMZ), histone deacetylases (HDACs), suberanilohydroxamic acid (SAHA), spectroscopic magnetic resonance imaging (sMRI), myo-inositol (MI), myo-inositol phosphatase (MIP), dimethyl sulfoxide (DMSO), Dulbecco’s modified eagle medium (DMEM), lipopolysaccharide (LPS), echo planar spectroscopic imaging (EPSI), T1-weighted (T1w), Inventory of Depressive Symptomatology Self Report (IDS-SR)

INTRODUCTION
Glioblastomas (GBMs; WHO grade IV glioma) are highly aggressive malignant primary adult brain tumors. Despite comprehensive treatment consisting of neurosurgical resection, high-dose radiation therapy (RT), and chemotherapy (temozolomide, TMZ), the median progression-free survival (PFS) remains 5–7 months (1). Given these poor results, there is an urgent need for improved therapy options. A potential therapeutic target is the family of histone deacetylases (HDACs) that comprises 18 different nuclear and cytoplasmic proteins primarily involved in modulating gene expression through epigenetic mechanisms but also having a broad impact on many additional pathways, including ones associated with cellular metabolism and cell cycle regulation (2–4). Several specific HDACs, particularly in class I and class II, show increased expression and are thought to contribute to oncogenesis in several types of cancer, including ones arising in breast, prostate, lung, and brain (5). As a result, the development of targeted HDAC inhibitors (HDACi) is an active research area for pharmacologic treatment of these diseases (6). In 2006, suberanilohydroxamic acid (SAHA), a first-generation HDACi which targets multiple class I and class II HDAC family members, became the first HDACi to receive FDA approval for advanced cutaneous T cell lymphomas (7). Preclinical investigations of SAHA have also shown antitumor effects in orthotopic glioma animal models (8, 9). This suggests that development of potent HDACis capable of penetrating the blood–brain barrier has the potential to improve therapeutic outcomes of patients with GBM. Research is ongoing into evaluating the synergistic effect of HDACi and chemoradiation for such patients (10).
Belinostat (PXD101, Spectrum Pharmaceuticals Inc., Irvine, CA), a new pan-HDACi that is structurally similar to SAHA, improves upon the former by having greater blood–brain barrier uptake, which may potentiate its use in the treatment of CNS tumors (11, 12). Belinostat received FDA approval for patients with relapsed/refractory peripheral T cell lymphoma in 2014 (13). In this work, we seek to show a translational analysis of belinostat in the treatment of GBM and describe how a quantitative imaging technique, proton spectroscopic magnetic resonance imaging (sMRI), can serve as a reliable imaging biomarker for monitoring therapy response of belinostat when combined with standard chemoradiation. First, we tested the antitumor effect of belinostat in an orthotopic rat glioma model. Second, we assessed the antidepressive effect of belinostat in 2 well-known depression animal models. We also quantified the increase of mRNA levels of bottleneck enzymes for the production of myo-inositol (MI), myo-inositol phosphatase (MIP), an sMRI-detectable metabolite known to be associated with depression. Finally, we assessed the impact of belinostat in combination with chemoradiation in a human pilot study (ClinicalTrials.gov ID: NCT02137759) and present interim results for PFS and a survey of depressive symptomatology. We present sMRI and clinical data from patients in this study to evaluate the modality’s use in monitoring response to belinostat + chemoradiation. Our results show a statistically significant improvement of depressive symptoms with belinostat treatment, consistent with our animal data. These results support the utility of belinostat as an adjuvant therapy for GBM and sMRI as a quantitative imaging technique that can noninvasively monitor therapy response.

**METHODOLOGY**

**Cell Culture and In Vitro HDACi Treatment**

Belinostat and other HDACis were dissolved in dimethyl sulfoxide (DMSO) to obtain a 100μM stock solution. A 9L rat glioma cell line was maintained in Dulbecco’s modified eagle medium (DMEM) (Mediatech Inc., Manassas, MA) supplemented with 10% fetal bovine serum and antibiotics at 37°C in 5% CO2. 9L cells were plated in 100-mm culture petri dishes. Cells were then treated 2 days following seeding with fresh medium containing various HDACis at concentrations of 1 μM for 12 h and were collected to prepare total RNA.

**RNA Isolation, RT-PCR, and Real-Time RT-PCR**

Cells were collected 12-hour postincubation; these cells underwent RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR) to assess the total mRNA expression levels of the key enzymes in the synthesis of MI (MIP) (8). Total RNA was extracted from cultured cells following the manufacturer’s instructions as previously described (14). Primer sequences of MIP-1 were as follows: MIP-1 (GenBank accession number: NM_016368), 5’- AGCTGCATCGAGAACATCCT –3’ and 5’-GGGTACCCTTCTCTTCTGT –3’; SYBR Green quantitative PCR reaction was carried out in a 15-μL reaction volume containing 2X PCR Master Mix (Applied Biosystems) per our previous reports (14).

**Antitumor Effect in an In Vivo Rat Glioma Model**

Using a previously described orthotopic rat glioma model (8), the tumoricidal and psychological effects of belinostat were tested. 9L rat glioma cells were stereotactically injected into the frontal lobes of male Fischer 344 rats (n = 9). At postinjection day 9, rats were treated with a daily intraperitoneal injection of either vehicle (10% DMSO, n = 1) or tiered doses of belinostat (n = 2 each of 25 mg/kg, 50 mg/kg, 75 mg/kg, and 100 mg/kg) for 4 days. Throughout the experiment, rats were monitored for mood behavior and activity levels using the volume of droppings as a surrogate measurement. Animals were sacrificed on postinjection day 12, and tumors were excised. This protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at Emory University.

**Antidepressive Effect Assessment of Belinostat in 2 Animal Models**

As described previously (15), the forced-swim test and tail suspension tests were used to assess the antidepressive effect of belinostat. Five 6-week-old C57 black female mice were used in each group for forced-swim test and five 7-week-old NIH Swiss male mice were used in each group for tail suspension test. C57 black mice may not perform well in the tail suspension test owing to tail climbing behavior (https://www.research.psu.edu/arp/experimental-guidelines/rodent-behavioral-tests-1/rodent-behavioral-tests.html), whereas the NIH Swiss mice did not have similar issues. The forced-swim test was performed 6 h after belinostat treatment (75 mg/kg i.p.) in a 4-L beaker containing 3 L of tap water at a temperature of 25°C. Video tracking–based methods were used to record the duration of time spent “immobile” in the arena over 6 minutes (immobility measured between 2 and 8 minutes of a 10-minute trial; the extent of immobility correlates with levels of depression). Similarly, the tail suspension test is based on the fact that animals subjected to inescapable stress of being suspended by their tail for the short term, would develop an immobile posture (16). For the tail suspension test, the lipopolysaccharide (LPS)-induced depression model was used (17). Twenty-four hours after LPS administration (Sigma L13129; 0.85 mg/kg i.p.), the tail suspension test was performed. Video tracking–based methods were used to record the duration of time spent in immobility for 6 minutes.

**Clinical Study**

Patients with newly diagnosed GBM were enrolled in either the control or treatment arm of an Institutional Review Board (IRB)-approved clinical trial at Emory University (ClinicalTrials.gov ID NCT02137759), wherein the treatment arm received intravenous belinostat (Spectrum Pharmaceuticals, Irvine, CA) as an investigational therapeutic. The study was not randomized, with patients serially enrolling into the control arm (in 2014–2015) followed by the belinostat treatment arm (in 2015–2018). All patients underwent maximal safe tumor resection, if resection was feasible, before enrolling in the study. Patients in both arms of the trial received standard-of-care therapy consisting of daily TMZ (75 mg/m²) × 42 days and focal radiation doses of 60 and 51 Gy to the resection cavity/residual contrast-enhancing tissue (per T1-weighted contrast-enhanced MRI postresection) and T2/FLAIR signal, respectively, in 30 fractions. Margins of 0.5–1.0 cm and 0.3–0.5 cm were added to the target volumes to generate the clinical treatment volume and planning treatment volume to account for microscopic disease spread and spatial uncertainty.
in treatment delivery (18). In the treatment arm, patients received daily intravenous doses of belinostat at either 500 or 750 mg/m² for 5 consecutive days in 3 cycles, spaced 3 weeks apart beginning 1 week before the start of chemoradiation, as shown in Figure 1. The first 3 patients received a higher dose of belinostat. However, because 2 of the patients had serious adverse events with hematologic toxicity during the course of belinostat, TMZ, and radiation, the dose was lowered to 500 mg/m² for the remaining patients in the trial.

Each patient in the study underwent an sMRI scan prior to starting chemoradiation (week 1), after 2 weeks of chemoradiation (week 3), and 4 weeks after completing radiation (week 11). Patients in the treatment arm underwent an additional sMRI scan before starting the first week of belinostat (week 0). sMRI scans were conducted on a 3 T MR scanner (Siemens TimTrio or Siemens PRISMA with 32 channel head coil, Siemens Healthineers, Erlangen, Germany) using an echo planar spectroscopic imaging (EPSI) sequence combined with generalized autocalibrating partially parallel acquisition (GRAPPA), and metabolite maps were produced using the MIDAS software (University of Miami, Miami, FL) (19, 20). The metabolite maps were coregistered to a volumetric T1-weighted (T1w) MRI taken during the same scanning session with the patient in the same orientation. Longitudinal scans on the 4 patients were coregistered and brought into the first scan (week 0) imaging space using rigid registration. After each sMRI scan, the patient completed the Inventory of Depressive Symptomatology Self Report (IDS-SR), a validated 30-question survey designed to assess depressive symptoms (21, 22).

EPSI/GRAPPA sequence parameters were optimized to enhance the signal of choline (Cho, a metabolite involved in the synthesis of the phospholipid cell membrane and increased in tumors) and NAA (a healthy neuronal marker decreased as neoplasia invades into and destroys neuronal tissue). Patients were followed-up with standard-of-care imaging (contrast-enhanced T1-weighted MRI, CE-T1w MRI; fluid attenuation inversion recovery, FLAIR) for 12 months post-treatment or until progression of disease was confirmed by neuroradiologist. A total of 26 patients (13 control, 13 treatment) were enrolled at Emory University; of these, 3 did not complete the treatment protocol (1 in control arm, 2 in belinostat arm), and 2 did not undergo surgical resection of tumor (only underwent a biopsy for diagnosis). These 5 patients are excluded from analysis (see online Supplemental Figure 1). PFS is reported for patients based on time to radiologic confirmation of disease progression (per CE-T1w MRI) from the date of surgery. Data are right-censored for patients who have no known disease progression or were lost to follow-up. Sample cases from each arm of the study are shown to show the ability of sMRI to identify early response to treatment. Because follow-up data are continuing to be collected for patients in the treatment arm of the study, statistical analyses of the full data will be presented in future work.

RESULTS

Antitumor Effect of Belinostat in an Orthotopic Rat Model

In Figure 2, photographs of the 9 rats evaluated in this experiment are shown in their cage at pretreatment with belinostat and at day 13, 4 days after treatment, when the rats were sacrificed. The volume of animal droppings seen in the cage is used as a surrogate measure of activity and normal physiology. Rats showed decreased movement and grooming, measures of mood, before treatment with belinostat. The restoration of activity and improved mood was observed in a dose-dependent manner, with normal levels observed in rats treated with the highest 2 doses (75 mg/kg and 100 mg/kg). Photographs of the tumor in situ and excised are also shown in Figure 2, showing a similar dose-dependent decrease in tumor volume from untreated mice through the increasing doses of belinostat.

<table>
<thead>
<tr>
<th>Week</th>
<th>Prior to enrollment</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>6mos</th>
<th>12mos</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical Resection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belinostat</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TMZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cycle 1 (42 days)</td>
</tr>
<tr>
<td>Radiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 fractions</td>
</tr>
<tr>
<td>sMRI Scan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDS-SR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurocognitive Testing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Imaging</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. One-year timeline of chemotherapy, intravenous belinostat, radiation, spectroscopic magnetic resonance imaging (sMRI) scanning, Inventory of Depressive Symptomatology Self Report (IDS-SR) survey, and neurocognitive testing for patients in NCT02137759. Hashed boxes indicate items conducted for patients in only the treatment arm of the study.
**Figure 2.** A rat model of stereotactically injected 9L glioma cells shows a dose-dependent response in both tumor volume and mood/activity levels when treated with belinostat.

**Table:**

<table>
<thead>
<tr>
<th>Group</th>
<th>Pre-Tx</th>
<th>Day 13</th>
<th>Tumor In Situ</th>
<th>Excised Tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td><img src="image" alt="Pre-Tx" /></td>
<td><img src="image" alt="Day 13" /></td>
<td><img src="image" alt="In Situ" /></td>
<td><img src="image" alt="Excised Tumor" /></td>
</tr>
<tr>
<td>25 mg/kg</td>
<td><img src="image" alt="Pre-Tx" /></td>
<td><img src="image" alt="Day 13" /></td>
<td><img src="image" alt="In Situ" /></td>
<td><img src="image" alt="Excised Tumor" /></td>
</tr>
<tr>
<td>50 mg/kg</td>
<td><img src="image" alt="Pre-Tx" /></td>
<td><img src="image" alt="Day 13" /></td>
<td><img src="image" alt="In Situ" /></td>
<td><img src="image" alt="Excised Tumor" /></td>
</tr>
<tr>
<td>75 mg/kg</td>
<td><img src="image" alt="Pre-Tx" /></td>
<td><img src="image" alt="Day 13" /></td>
<td><img src="image" alt="In Situ" /></td>
<td><img src="image" alt="Excised Tumor" /></td>
</tr>
<tr>
<td>100 mg/kg</td>
<td><img src="image" alt="Pre-Tx" /></td>
<td><img src="image" alt="Day 13" /></td>
<td><img src="image" alt="In Situ" /></td>
<td><img src="image" alt="Excised Tumor" /></td>
</tr>
</tbody>
</table>

**Figure 3.** Two mouse models of depression to assess antidepressive effect of belinostat: Force-swim test measuring the time spent in immobility during 2–8 minutes (6 minutes) (A). Tail suspension test measuring the time spent in immobility in mice treated with lipopolysaccharide (LPS) for 6 minutes. Five mice were used in each group (B).
Antidepression Effect of Belinostat in 2 Animal Models

Figure 3 shows the results of the forced-swim and tail suspension tests. In the forced-swim test, the mice who received belinostat spent less time immobile compared to the control mice ($P = .14$). In the tail suspension test, the mice who received LPS + belinostat had a statistically significant decrease in immobility compared with mice who received LPS alone ($P = .02$).

In Vitro Study of mRNA Expression

mRNA expression levels of MIP (a bottleneck enzyme in the production of MI) from HDACi-treated cells are shown in online Supplemental Figure 2 as fold-increases in log-scale compared with those of the untreated cells (DMSO vehicle control). Belinostat showed greater increases in restoration of mRNA levels at the same concentration as other HDACi, including SAHA. The only other HDACi which achieved greater efficacy is quisinostat (JNJ26481585, Janssen Pharmaceuticals, Beerse, Belgium), a second-generation pan-HDACi, which was being tested in phase II clinical trials for multiple myeloma (23). However, currently there are no active trials for quisinostat on ClinicalTrials.gov.

Clinical Study

In total, 21 patients who met inclusion criteria for analysis were assessed to determine differences in PFS between the 2 arms (see online Supplemental Figure 1). A table summarizing basic demographics of the 2 arms of the clinical study is shown in Figure 4A. Both arms showed similar distributions of known genetic targets that improve response to radiation—mutation of isocitrate dehydrogenase 1 (IDH1) and promoter methylation of the gene for 0-(6)-methylguanine-DNA methyltransferase (24).

Figure 4B shows Kaplan–Meier curves for PFS from date of surgery (tick marks indicate time of censoring). Six-month PFS was 73% for the control arm and 100% for the belinostat arm. A log-rank test assessing PFS data up to 6 months trended toward statistical significance ($P = .09$). No statistically significant difference was observed on a log-rank test assessing PFS data up to 12 months ($P = .45$). Of these 21 patients, 17 completed an IDS-SR survey at both baseline (week 0 for belinostat arm, week

<table>
<thead>
<tr>
<th>Table 1. IDS-SR Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Number of Patients</td>
</tr>
<tr>
<td>Baseline Score</td>
</tr>
<tr>
<td>Week 11 Score</td>
</tr>
<tr>
<td>Change in Score</td>
</tr>
</tbody>
</table>

The IDS-SR assessment of patients in both study arms between baseline and 1-month post-RT shows a statistically significant improvement in assessment scores for patients who received belinostat. $P$ values indicate results of a two-tailed unpaired t-test.
1 for control arm) and at week 11 (see online Supplemental Figure 2; Table 1). While no significant difference in the scores was observed at either time point, the belinostat cohort had a statistically significant improvement in scores over the course of treatment using a 2-tailed unpaired $T$ test ($P < .04$).

Figures 5 and 6 depict sMRI and clinical CE-T1w MRI scans for 2 representative patients, 1 from each of the study arms. At baseline, both patients showed elevated choline metabolism (red arrows) around the resection cavities, indicating the presence of increased cellular turnover associated with neoplasia. One-month post-RT (week 11), both patients showed decreased levels of choline compared with baseline, and low NAA levels owing to subsequent radiation damage to in-field neurons. Therefore, Cho/NAA did not reliably indicate early response (see online Supplemental Figure 3); however, we found that peritumoral MI was improved in the subject who received belinostat (see online Supplemental Figure 3) at 1-month post-RT. The control patient (Figure 5) was deemed to have potential progression of her disease because of the thickened contrast enhancement around the resection cavity on CE-T1w imaging; a month later, however, the thickened contrast rim was gone, and the patient was deemed to not yet have disease progression. The patient in the belinostat arm (Figure 6) had a similar course; only the increase in enhancement occurred 3 months after radiation was completed.

**DISCUSSION**

In this work, we sought to characterize the antitumor and antidepressant activity of belinostat, a new HDACi with improved brain penetration, in a translational manner: starting from in
vivo animal glioma models to testing in patients with glioblastoma. First, we assessed the efficacy of belinostat in reducing tumor volume in an orthotopic rat glioma model. Here, a dose-dependent reduction in tumor size was observed, suggesting the antitumor properties of the drug are effective in crossing the blood–brain barrier in vivo (Figure 2). In addition, it was observed that the activity levels of rats, as measured by grooming activities and droppings, were higher in those treated with increased doses of belinostat. These improvements are consistent with previously reported literature by Covington et al. (25) that HDACis possess antidepressant properties. To further assess the antidepressive effect of belinostat, we subjected mice to two different models of induced depression. We found that belinostat reduced the immobility time in both the forced-swim and tail suspension tests (Figure 3), exhibiting the drug’s antidepressant effect. We followed these tests with an in vitro assessment of belinostat’s effect on MIP, the key enzyme in the production of MI that was implicated in depression. The in vitro cell study showed that belinostat had greater restorative activity for MIP than most other HDACis. An HDACi tested that had higher restoration than belinostat was quisinostat (JNJ26481585); however, there is no clinical trial currently enrolling patients testing quisinostat. As such, belinostat shows promise as a targeted HDACi for glioblastoma because of its increased uptake into the brain and its efficacy in restoring key metabolic activity for depression.

The belinostat clinical trial completed enrollment of patients in August 2018, and patients are continuing to be followed to assess long-term outcomes including progression-free and overall survival. Although statistical claims cannot yet be made regarding long-term survival and efficacy, a comparison of 6-month PFS and initial changes in mood are presented in this work. The cohort receiving belinostat showed a trend of improved 6-month PFS compared to the control cohort (P = .09); however, this difference was mitigated by 12 months (P = .45). Despite a limited sample size for this study, these results suggest that belinostat may improve response to chemoradiation therapy as hypothesized. A speculated reason for the improved PFS at 6 months but not at 12 months is that belinostat was given to subjects for only a short term during RT.

While 6-month PFS outcomes approached statistical significance, the belinostat cohort did achieve a statistically significant improvement in depression as measured by the IDS-SR (P = .04). This suggests that the mood improvement effect of belinostat, as shown in our animal data and with the claim by Covington et al. (25), may translate to humans. These preliminary data suggest future large cohorts to be evaluated.

Finally, this study showed the potential of sMRI as a non-invasive monitoring tool for investigational therapeutics. As shown in Figures 5 and 6, both patients appeared to have a reduced tumor burden when assessing choline metabolism at week 1, 1 month after the completion of RT. Owing to radiation-induced damage, NAA was reduced around the high dose area, which made Cho/NAA ineffective in assessing tumor response (see online Supplemental Figure 3). MI showed a slight improvement back towards normal level at the 1-month post-RT scan in the patient treated with belinostat, consistent with IDS-SR score improvement (see online Supplemental Figure 3). Further studies, including longitudinal scanning, are needed to fully elucidate the timeline of metabolite changes in these patients. Standard imaging, however, differed between the 2 patients and suggested that the control patient may have been experiencing disease progression, when eventually it turned out to be stable disease at that time. This is a phenomenon known as pseudo-progression, the ambiguity of CE-T1w findings in differentiating true progression of disease from normal tissue response to high-dose radiation. sMRI, however, is robust to the pseudoprogression phenomenon, as the modality is measuring endogenous intracellular metabolism rather than vasculature damages/changes or tissue phenomena such as edema. Both patients showed similar metabolic signatures, which turned out to be more accurate of the underlying pathology compared to clinical imaging.

CONCLUSION
In this work we described the therapeutic and antitumor, antidepressive effects of belinostat, a potent pan-HDACi with blood–brain barrier permeability through: a rat glioma model, 2 mouse depression models, an in vitro cell study, and testing in a pilot clinical study in patients with glioblastoma. The results from this work suggest that belinostat may be an effective HDACi at delaying disease progression and improving depression. Furthermore, it shows that the treatment response can be monitored noninvasively using spectroscopic MRI during pseudoprogression period. Further studies and analysis of the ongoing clinical trial may yield a better understanding of the role that HDACis play in the metabolic profiles of GBM and motivate the development of better, targeted therapies for patients with this debilitating disease.

Additional testing of this drug in human subjects can help with separating this improved mood/activity effect due to a primary property of HDACis from improvement as a secondary effect to reduced tumor burden.

Supplemental Materials
Supplemental Figure 1-3: http://dx.doi.org/10.18383/j.tom.2018.00031.sup.01

ACKNOWLEDGMENTS
We would like to thank Spectrum Pharmaceuticals for providing the investigational drug used in this clinical study; the staff at the Clinical Trials Office at the Winship Cancer Institute for their support and assistance with recruiting and managing the patients enrolled in the clinical study; and Dr. Andrew Maudsley and Mr. Sulaiman Sheriff at the University of Miami for their support with the EPSI sequence and MIDAS software framework. Funding for this work came from National Institutes of Health grant U01CA172027.

Disclosures: No disclosures to report.
Conflict of Interest: The authors have no conflict of interest to declare.
REFERENCES


